Rabbit Recombinant Monoclonal PIAS1 antibody. Suitable for IHC-P, WB, ICC/IF and reacts with Human, Synthetic peptide - Human, Mouse, Rat samples. Cited in 18 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
IHC-P | WB | ICC/IF | |
---|---|---|---|
Human | Tested | Tested | Tested |
Mouse | Predicted | Expected | Predicted |
Rat | Predicted | Expected | Predicted |
Synthetic peptide - Human | Not recommended | Tested | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 - 1/250 | Notes Perform heat-mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide - Human | Dilution info 1/1000 - 1/10000 | Notes - |
Species Human | Dilution info 1/1000 - 1/10000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 - 1/500 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide - Human | Dilution info - | Notes - |
Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor (PubMed:11583632, PubMed:11867732, PubMed:14500712, PubMed:21965678, PubMed:36050397). Catalyzes sumoylation of various proteins, such as CEBPB, MRE11, MTA1, PTK2 and PML (PubMed:11583632, PubMed:11867732, PubMed:14500712, PubMed:21965678, PubMed:36050397). Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway (PubMed:11583632, PubMed:11867732). In vitro, binds A/T-rich DNA (PubMed:15133049). The effects of this transcriptional coregulation, transactivation or silencing, may vary depending upon the biological context (PubMed:11583632, PubMed:11867732, PubMed:14500712, PubMed:21965678, PubMed:36050397). Mediates sumoylation of MRE11, stabilizing MRE11 on chromatin during end resection (PubMed:36050397). Sumoylates PML (at 'Lys-65' and 'Lys-160') and PML-RAR and promotes their ubiquitin-mediated degradation (By similarity). PIAS1-mediated sumoylation of PML promotes its interaction with CSNK2A1/CK2 which in turn promotes PML phosphorylation and degradation (By similarity). Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation (PubMed:21965678). Plays a dynamic role in adipogenesis by promoting the SUMOylation and degradation of CEBPB (By similarity). Mediates the nuclear mobility and localization of MSX1 to the nuclear periphery, whereby MSX1 is brought into the proximity of target myoblast differentiation factor genes (By similarity). Also required for the binding of MSX1 to the core enhancer region in target gene promoter regions, independent of its sumoylation activity (By similarity). Capable of binding to the core enhancer region TAAT box in the MYOD1 gene promoter (By similarity). (Microbial infection) Restricts Epstein-Barr virus (EBV) lytic replication by acting as an inhibitor for transcription factors involved in lytic gene expression (PubMed:29262325). The virus can use apoptotic caspases to antagonize PIAS1-mediated restriction and express its lytic genes (PubMed:29262325).
PIAS2
DDXBP1, PIAS1, E3 SUMO-protein ligase PIAS1, DEAD/H box-binding protein 1, E3 SUMO-protein transferase PIAS1, Gu-binding protein, Protein inhibitor of activated STAT protein 1, RNA helicase II-binding protein, GBP
Rabbit Recombinant Monoclonal PIAS1 antibody. Suitable for IHC-P, WB, ICC/IF and reacts with Human, Synthetic peptide - Human, Mouse, Rat samples. Cited in 18 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
PIAS1 and PIAS2 which stand for Protein Inhibitor of Activated STAT1 and STAT2 respectively are members of the PIAS protein family. These proteins are known to function as E3 SUMO-protein ligases and play a significant role in the post-translational modification process called SUMOylation. PIAS1 has a mass of about 71 kDa and PIAS2 has a mass of approximately 73 kDa. PIAS1 and PIAS2 are expressed in various tissues with high expression observed in the brain and hematopoietic cells.
PIAS1 and PIAS2 play essential roles in modulating key signaling pathways through SUMOylation. They often work as part of larger protein complexes modulating the activity of transcription factors such as STAT p53 and NF-kB. By affecting these transcription factors PIAS proteins can regulate gene expression thereby influencing cell proliferation differentiation and response to stress. This involvement in gene regulation underlines their importance in maintaining cellular homeostasis.
PIAS1 and PIAS2 contribute to critical processes like the JAK-STAT signaling pathway and the NF-kB signaling pathway. These pathways are influential in controlling immune responses. Through phosphorylation and interaction with other transcription factors like STAT1 and NF-kB PIAS proteins alter the transcriptional activity of genes involved in inflammation and cellular stress responses. The modulation of these pathways links PIAS1 and PIAS2 with both immune and stress responses playing a role in both normal and pathological conditions.
PIAS1 and PIAS2 are associated with chronic inflammation and cancer. Their regulatory role in the JAK-STAT and NF-kB pathways connects them to inflammatory diseases where dysregulation of these pathways is common. Additionally PIAS1 and PIAS2 interact with proteins like p53 linking them to tumor suppression and anomalies in their expression or function can contribute to the development of cancers. Understanding these associations is important for developing therapies targeting these signaling proteins.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking and Diluting buffer and concentration: 5% NFDM /TBST
Exposure time: Lane1:10 seconds, Lane2: 5 seconds, Lane3: 3 minutes.
Human PIAS1 full-length recombinant protein (Cat#: ab152888)
All lanes: Western blot - Anti-PIAS1 + PIAS2 antibody [EPR2581Y] (ab77231) at 1/50000 dilution
Lane 1: Human PIAS1 full-length recombinant protein with GST-Tag at 0.015 µg
Lane 2: Human PIAS2-beta recombinant protein fragment with GST-His-Tag at 0.015 µg
Lane 3: Human PIAS3 recombinant protein fragment with SUMO-His-Tag at 0.015 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 72 kDa
Observed band size: 42 kDa, 98 kDa
All lanes: Western blot - Anti-PIAS1 + PIAS2 antibody [EPR2581Y] (ab77231) at 1/50000 dilution
Lane 1: Daudi cell lysate at 10 µg
Lane 2: 293 cell lysate at 10 µg
Lane 3: Jurkat cell lysate at 10 µg
Lane 4: SW40 cell lysate at 10 µg
Lane 5: HepG2 cell lysate at 10 µg
All lanes: HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 72 kDa
Observed band size: 78 kDa
Immunocytochemistry/Immunofluorescence analysis of HeLa (human cervix adenocarcinoma) cells labelling PIAS1 + PIAS2 with purified ab77231 at 1/500. Cells were fixed with 4% Paraformaldehyde and permeabilized with 0.1% Triton X-100. Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077, Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. Nuclei were counterstained with DAPI (blue).
Secondary Only Control: PBS was used instead of the primary antibody as the negative control.
ab77231, at a 1/100 dilution, staining PIAS1 + PIAS2 in paraffin embedded human tonsil tissue by Immunohistochemistry.
Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com